Abstracts tagged "molecular signature"

Abstract Number: 1252 • ACR Convergence 2021
Discontinuation of TNFi Treatment Among Rheumatoid Arthritis Patients with a Molecular Signature of Non-response to Tumor Necrosis Factor-ɑ Inhibitor Therapies
Jeffrey Curtis¹, Joel Kremer², Dimitrios Pappas³, Lixia Zhang⁴, Erin Connolly-Strong⁵, Johanna Withers⁴, Viatcheslav Akmae⁴ and Alif Saleh⁴, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Albany Medical College, Latham, NY, ³CorEvitas, LLC, Waltham, MA, ⁴Scipher Medicine, Waltham, MA, ⁵Scipher Medicine, Austin, TX
Background/Purpose: A 23-feature blood-based molecular signature response classifier1 (MSRC) identifies rheumatoid arthritis (RA) patients who are unlikely to respond to tumor necrosis factor-ɑ inhibitor (TNFi)…
Abstract Number: 1255 • ACR Convergence 2021
A Molecular Signature Response Classifier Predicts the Likelihood of Non-response to TNF Inhibitor Therapies in RA at 3 Months
Stanley Cohen¹, Theodore Mellors², Lixia Zhang³, Alex Jones³, Erin Connolly-Strong⁴, Dimitrios Pappas⁵, Joel Kremer⁶, Johanna Withers³ and Viatcheslav Akmae³, ¹Metroplex Clinical Research Center, Dallas, TX, ²Scipher Medicine, Waltham, TX, ³Scipher Medicine, Waltham, MA, ⁴Scipher Medicine, Austin, TX, ⁵CorEvitas, LLC, Waltham, MA, ⁶Albany Medical College, Latham, NY
Background/Purpose: Most people with rheumatoid arthritis (RA) are prescribed a TNF inhibitor (TNFi) as their first targeted therapy. A blood-based molecular signature response classifier (MSRC)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].